NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system (CNS) disorders, ...
The traditional “ monoamine hypothesis ” of depression was proposed more than half a century ago, in the 1950s. This theory ...
A single intravenous dose of dimethyltryptamine, the psychoactive compound found in the Amazonian brew ayahuasca, produced significant and lasting reductions in depression symptoms across a ...
No single ‘depression gene’ has been found, but large studies have identified over 100 genetic risk markers on chromosomes ...